Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Narazaciclib - Traws Pharma

Next Previous
Drug Profile

Narazaciclib - Traws Pharma

Alternative Names: HX-301; ON-123300

Latest Information Update: 25 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Temple University
  • Developer HanX Biopharmaceuticals; Traws Pharma
  • Class 2 ring heterocyclic compounds; Aniline compounds; Antineoplastics; Cyclopentanes; Nitriles; Piperidines; Pyridines; Pyrimidines; Small molecules
  • Mechanism of Action Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors; NUAK1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Phase II Cancer
  • Phase I/II Endometrial cancer
  • Phase I Solid tumours
  • Preclinical Breast cancer; Mantle-cell lymphoma; Ovarian cancer
  • No development reported Colorectal cancer

Most Recent Events

  • 23 Apr 2024 Phase-II clinical trials in Cancer in China (PO) (Prior to April 2024)
  • 23 Apr 2024 Pharmacodynamics data from preclinical study in Acute myeloid leukemia released by HanX Biopharmaceuticals
  • 08 Apr 2024 Onconova Therapeutics plans a phase I/II trial for Multiple myeloma(Second-line therapy or greater, Combination therapy) in USA (PO, Capsule) in June 2024 (NCT06351644)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top